SMT201300112B - Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene - Google Patents

Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene

Info

Publication number
SMT201300112B
SMT201300112B SM201300112T SM201300112T SMT201300112B SM T201300112 B SMT201300112 B SM T201300112B SM 201300112 T SM201300112 T SM 201300112T SM 201300112 T SM201300112 T SM 201300112T SM T201300112 B SMT201300112 B SM T201300112B
Authority
SM
San Marino
Prior art keywords
citrate salt
nonaene
triaza
pyrrolidin
ethoxy
Prior art date
Application number
SM201300112T
Other languages
English (en)
Italian (it)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of SMT201300112B publication Critical patent/SMT201300112B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SM201300112T 2009-07-15 2013-10-04 Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene SMT201300112B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (1)

Publication Number Publication Date
SMT201300112B true SMT201300112B (it) 2013-11-08

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300112T SMT201300112B (it) 2009-07-15 2013-10-04 Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene

Country Status (19)

Country Link
US (1) US9062074B2 (pl)
EP (1) EP2454266B1 (pl)
JP (2) JP6013911B2 (pl)
CN (1) CN102762577B (pl)
AR (2) AR077483A1 (pl)
BR (1) BR112012000750B1 (pl)
CA (1) CA2768210C (pl)
DK (1) DK2454266T3 (pl)
ES (1) ES2429525T3 (pl)
HK (1) HK1178159A1 (pl)
HR (1) HRP20130941T1 (pl)
MX (1) MX2012000680A (pl)
PL (1) PL2454266T3 (pl)
PT (1) PT2454266E (pl)
RU (1) RU2543721C2 (pl)
SI (1) SI2454266T1 (pl)
SM (1) SMT201300112B (pl)
TW (1) TWI537276B (pl)
WO (1) WO2011008172A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
MX2018007154A (es) 2015-12-15 2019-01-10 Context Biopharma Inc Composiciones de onapristona amorfa y metodos para hacer las mismas.
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR101499594B1 (ko) 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체

Also Published As

Publication number Publication date
JP6013911B2 (ja) 2016-10-25
JP2015164941A (ja) 2015-09-17
CN102762577A (zh) 2012-10-31
CA2768210A1 (en) 2011-01-20
BR112012000750A2 (pt) 2016-08-09
EP2454266A1 (en) 2012-05-23
RU2543721C2 (ru) 2015-03-10
TW201107336A (en) 2011-03-01
TWI537276B (zh) 2016-06-11
WO2011008172A1 (en) 2011-01-20
HRP20130941T1 (hr) 2013-11-08
PL2454266T3 (pl) 2014-01-31
AR077483A1 (es) 2011-08-31
US20120196876A1 (en) 2012-08-02
AR114987A2 (es) 2020-11-11
MX2012000680A (es) 2012-02-28
CN102762577B (zh) 2015-01-07
PT2454266E (pt) 2013-10-10
EP2454266B1 (en) 2013-07-10
CA2768210C (en) 2017-08-15
JP2012533539A (ja) 2012-12-27
HK1178159A1 (en) 2013-09-06
US9062074B2 (en) 2015-06-23
RU2012105044A (ru) 2013-08-20
BR112012000750A8 (pt) 2018-02-06
BR112012000750B1 (pt) 2021-05-25
DK2454266T3 (da) 2013-09-08
SI2454266T1 (sl) 2013-10-30
ES2429525T3 (es) 2013-11-15

Similar Documents

Publication Publication Date Title
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
IN2012DN01233A (pl)
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
UA115983C2 (uk) Інгібітори днк-пк
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
IN2015DN01151A (pl)
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
WO2013040227A3 (en) Therapeutic compounds
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用